{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:08:37Z","timestamp":1790226517336,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ijrobp.2017.06.2466","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T17:52:19Z","timestamp":1498845139000},"page":"797-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma"],"prefix":"10.1016","volume":"99","author":[{"given":"Jennifer","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Terziev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Gutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Barani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Lassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ase","family":"Ballangrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine S.","family":"Panageas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Beal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Omuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2017.06.2466_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/cancers4010257","article-title":"Radiation therapy for the treatment of recurrent glioblastoma: An overview","volume":"4","author":"Amelio","year":"2012","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib3","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib4","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib5","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: A clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/030089161309900407","article-title":"Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma","volume":"99","author":"Yoon","year":"2013","journal-title":"Tumori"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1586\/14737140.2016.1143364","article-title":"External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma","volume":"16","author":"Taunk","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/2211552811201030169","article-title":"Combining bevacizumab with radiation or chemoradiation for solid tumors: A review of the scientific rationale, and clinical trials","volume":"1","author":"Schmidt","year":"2012","journal-title":"Curr Angiogenes"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijrobp.2008.10.043","article-title":"Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas","volume":"75","author":"Gutin","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib10","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ijrobp.2012.05.031","article-title":"Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma","volume":"85","author":"Shapiro","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib11","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system","volume":"79","author":"Levin","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2010.09.002","article-title":"Irradiation and bevacizumab in high-grade glioma retreatment settings","volume":"82","author":"Niyazi","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib13","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ijrobp.2010.12.074","article-title":"Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas","volume":"82","author":"Cuneo","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib14","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1158\/1078-0432.CCR-14-0822","article-title":"Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma","volume":"20","author":"Omuro","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib15","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib16","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/B978-0-444-53502-3.00030-6","article-title":"Complications of radiotherapy to the central nervous system","volume":"105","author":"Omuro","year":"2012","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11060-013-1126-2","article-title":"Hypofractionated stereotactic radiotherapy for unifocal and multifocal recurrence of malignant gliomas","volume":"113","author":"McKenzie","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00066-009-1753-x","article-title":"Hypofractionated stereotactic reirradiation of recurrent glioblastomas: A beneficial treatment option after high-dose radiotherapy?","volume":"185","author":"Fokas","year":"2009","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00066-009-1969-9","article-title":"Hypofractionated reirradiation for recurrent malignant glioma","volume":"185","author":"Henke","year":"2009","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ijrobp.2005.01.056","article-title":"Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)\/CT\/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy","volume":"63","author":"Grosu","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2407-5-55","article-title":"Hypofractionated stereotactic re-irradiation: Treatment option in recurrent malignant glioma","volume":"5","author":"Vordermark","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0360-3016(98)00416-7","article-title":"A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma","volume":"43","author":"Hudes","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0360-3016(96)00455-5","article-title":"Hypofractionated stereotactic radiotherapy in the management of recurrent glioma","volume":"37","author":"Shepherd","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11060-014-1524-0","article-title":"Hypofractionated stereotactic reirradiation for recurrent glioblastoma","volume":"120","author":"Yazici","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib25","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/cam4.154","article-title":"Efficacy of salvage stereotactic radiotherapy for recurrent glioma: Impact of tumor morphology and method of target delineation on local control","volume":"2","author":"Ogura","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/1748-717X-8-222","article-title":"Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: Single institutional experience","volume":"8","author":"Ciammella","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s00066-013-0390-6","article-title":"Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy. Technical considerations based on experience at a single institution","volume":"189","author":"Mizumoto","year":"2013","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/030089161109700111","article-title":"Treatment of recurrent glioblastoma with stereotactic radiotherapy: Long-term results of a mono-institutional trial","volume":"97","author":"Maranzano","year":"2011","journal-title":"Tumori"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11060-008-9752-9","article-title":"Salvage reirradiation for recurrent glioblastoma with radiosurgery: Radiographic response and improved survival","volume":"92","author":"Patel","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib30","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.1200\/JCO.2005.03.4157","article-title":"Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution","volume":"23","author":"Combs","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-012-0999-9","article-title":"Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas","volume":"111","author":"Minniti","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib32","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","article-title":"Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas","volume":"28","author":"Fogh","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib33","first-page":"304","article-title":"Survival following reirradiation using intensity-modulated radiation therapy with temozolomide in selected patients with recurrent high grade gliomas","volume":"3","author":"Aktan","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib34","first-page":"44","article-title":"Phase II trial of temozolomide and reirradiation using conformal 3D-radiotherapy in recurrent brain gliomas","volume":"2","author":"Osman","year":"2014","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib35","first-page":"657953","article-title":"Salvage radiosurgery for selected patients with recurrent malignant gliomas","volume":"201","author":"Martinez-Carrillo","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00701-011-1184-1","article-title":"Efficacy and toxicity of CyberKnife re-irradiation and \u201cdose dense\u201d temozolomide for recurrent gliomas","volume":"154","author":"Conti","year":"2012","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-008-9607-4","article-title":"Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas","volume":"89","author":"Combs","year":"2008","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11060-015-1745-x","article-title":"Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas","volume":"122","author":"Minniti","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijrobp.2012.04.017","article-title":"A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas","volume":"85","author":"Den","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ijrobp.2014.05.034","article-title":"A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma","volume":"90","author":"Wuthrick","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib41","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.ijrobp.2008.06.1919","article-title":"Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas","volume":"73","author":"Schwer","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib42","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11060-016-2059-3","article-title":"Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas","volume":"127","author":"Shi","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11060-014-1394-5","article-title":"Re-irradiation and bevacizumab in recurrent high-grade glioma: An effective treatment option","volume":"117","author":"Flieger","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib45","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12325-011-0007-3","article-title":"AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme","volume":"28","author":"Chinot","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib46","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.06.2466_bib47","first-page":"48","article-title":"Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma","volume":"2","author":"Back","year":"2015","journal-title":"Neurooncol Pract"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617335496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617335496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T01:25:52Z","timestamp":1569633952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301617335496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0360301617335496"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.06.2466","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.06.2466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}